U.S. markets open in 1 hour 9 minutes
  • S&P Futures

    3,864.25
    +16.00 (+0.42%)
     
  • Dow Futures

    31,177.00
    +164.00 (+0.53%)
     
  • Nasdaq Futures

    11,940.50
    +60.25 (+0.51%)
     
  • Russell 2000 Futures

    1,738.10
    +9.50 (+0.55%)
     
  • Crude Oil

    99.84
    +1.31 (+1.33%)
     
  • Gold

    1,742.50
    +6.00 (+0.35%)
     
  • Silver

    19.31
    +0.15 (+0.76%)
     
  • EUR/USD

    1.0187
    +0.0003 (+0.03%)
     
  • 10-Yr Bond

    2.9130
    0.0000 (0.00%)
     
  • Vix

    26.53
    -1.01 (-3.67%)
     
  • GBP/USD

    1.1972
    +0.0050 (+0.42%)
     
  • USD/JPY

    135.7360
    -0.1790 (-0.13%)
     
  • BTC-USD

    20,490.25
    +463.09 (+2.31%)
     
  • CMC Crypto 200

    446.05
    +10.53 (+2.42%)
     
  • FTSE 100

    7,193.95
    +86.18 (+1.21%)
     
  • Nikkei 225

    26,490.53
    +382.88 (+1.47%)
     

Even though Horizon Therapeutics (NASDAQ:HZNP) has lost US$862m market cap in last 7 days, shareholders are still up 453% over 5 years

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

It hasn't been the best quarter for Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) shareholders, since the share price has fallen 19% in that time. But over five years returns have been remarkably great. In fact, during that period, the share price climbed 453%. Impressive! So we don't think the recent decline in the share price means its story is a sad one. Only time will tell if there is still too much optimism currently reflected in the share price.

In light of the stock dropping 4.0% in the past week, we want to investigate the longer term story, and see if fundamentals have been the driver of the company's positive five-year return.

See our latest analysis for Horizon Therapeutics

While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

During the five years of share price growth, Horizon Therapeutics moved from a loss to profitability. That kind of transition can be an inflection point that justifies a strong share price gain, just as we have seen here.

You can see below how EPS has changed over time (discover the exact values by clicking on the image).

earnings-per-share-growth
earnings-per-share-growth

It is of course excellent to see how Horizon Therapeutics has grown profits over the years, but the future is more important for shareholders. This free interactive report on Horizon Therapeutics' balance sheet strength is a great place to start, if you want to investigate the stock further.

A Different Perspective

Horizon Therapeutics' TSR for the year was broadly in line with the market average, at 16%. We should note here that the five-year TSR is more impressive, at 41% per year. More recently, the share price growth has slowed. But it has to be said the overall picture is one of good long term and short term performance. Arguably that makes Horizon Therapeutics a stock worth watching. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Take risks, for example - Horizon Therapeutics has 3 warning signs we think you should be aware of.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.